Coles AJ - Search Results

1

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Cohen JA, et al. Among authors: coles aj. Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122652 Clinical Trial.

2

T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation.

O'Riordan JI, Gawne Cain M, Coles A, Wang L, Compston DA, Tofts P, Miller DH. O'Riordan JI, et al. Mult Scler. 1998 Oct;4(5):408-12. doi: 10.1177/135245859800400502. Mult Scler. 1998. PMID: 9839300

3

Multiple sclerosis.

Compston A, Coles A. Compston A, et al. Lancet. 2002 Apr 6;359(9313):1221-31. doi: 10.1016/S0140-6736(02)08220-X. Lancet. 2002. PMID: 11955556 Review.

4

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ. Cox AL, et al. Among authors: coles aj. Eur J Immunol. 2005 Nov;35(11):3332-42. doi: 10.1002/eji.200535075. Eur J Immunol. 2005. PMID: 16231285 Free article. Clinical Trial.

5

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

CAMMS223 Trial Investigators; Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. CAMMS223 Trial Investigators, et al. Among authors: coles aj. N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670. N Engl J Med. 2008. PMID: 18946064 Free article. Clinical Trial.

6

Multiple sclerosis.

Compston A, Coles A. Compston A, et al. Lancet. 2008 Oct 25;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7. Lancet. 2008. PMID: 18970977 Free article.

7

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. Thompson SA, et al. Among authors: coles aj. J Clin Immunol. 2010 Jan;30(1):99-105. doi: 10.1007/s10875-009-9327-3. Epub 2009 Sep 10. J Clin Immunol. 2010. PMID: 19763798

8

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ. Jones JL, et al. Among authors: coles aj. Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21. Brain. 2010. PMID: 20659956 Clinical Trial.

9

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Coles AJ, et al. Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5. Lancet Neurol. 2011. PMID: 21397567 Clinical Trial.

10

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, Purvis A, Beardsley DS, Margolin DH. Cuker A, et al. Among authors: coles aj. Blood. 2011 Dec 8;118(24):6299-305. doi: 10.1182/blood-2011-08-371138. Epub 2011 Sep 29. Blood. 2011. PMID: 21960587 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

167 results

Search Page